Clinical Trial Update: A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

This is an update on a Phase 3 randomized, double-blind, placebo-controlled trial of Oralgen Grass Pollen for allergic rhinoconjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Oralgen Grass Pollen

Snippet

Sponsor: Artu Biologicals | Conditions: Allergic Rhinoconjunctivitis | Phase 3 | Status: UNKNOWN